АА

А. А. Курылев

First Pavlov State Medical University of St. Petersburg

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

АС

А. С. Колбин

St Petersburg University

МА

М. А. Проскурин

St Petersburg University

YЕ

Yu. Е. Balykina

St Petersburg University

ЮЕ

Ю Е Балыкина

St Petersburg University

Sidorenko Sv

North-Western State Medical University named after I.I. Mechnikov

SА

S. А. Mishinova

First Pavlov State Medical University of St. Petersburg

Yu. V. Lobzin

North-Western State Medical University named after I.I. Mechnikov

ТЛ

Т. Л. Галанкин

First Pavlov State Medical University of St. Petersburg

Dmitry O. Ivanov

Saint Petersburg State Pediatric Medical University

Maria A. Arepeva

St Petersburg University

Cooperative Institutions

Ministry of Health of the Russian Federation

First Pavlov State Medical University of St. Petersburg

St Petersburg University

North-Western State Medical University named after I.I. Mechnikov

S. M. Kirov Military Medical Academy

Sechenov University

St.Petersburg V.M.Bekhterev Psychoneurological Research Institute

Saint Petersburg State Pediatric Medical University

Federal Almazov North-West Medical Research Centre

Russian Medical Academy of Continuous Professional Education

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Pharmacoeconomic analysis of insulin aspart+nicotinamide versus insulin aspart in patients with diabetes mellitus

Pharmacoeconomics theory and practice (2021)

А. С. Колбин А. А. Курылев Yu.Ye. Balykina М. А. Проскурин S. А. Mishinova

Glycemic control is a clinical goal in the treatment of diabetes mellitus. Currently available bolus insulin analogues do not follow the physiological pattern of insulin secretion after meals because they are slowly absorbed from the injection site. Insulin aspart+nicotinamide is an ultra-fast acting human insulin analog that can be administered before or after meals and the nicotinamide (vitamin B3) molecule provides optimal glycemic control. Aim. To evaluate clinical and economic efficacy of the drug insulin aspart+nicotinamide in comparison with insulin aspart in patients with diabetes mellitus. Materials and Methods. Clinical and economic analysis was performed in accordance with the standards and recommendations valid in the Russian Federation, the method of cost-effectiveness analysis for the first model population of patients with type 1 diabetes and the method of cost-minimization analysis for the second model population of patients with type 2 diabetes, modeling horizon was 26 weeks. Since the study is conducted from the per- spective of the health care system only direct medical costs were considered, that is, the cost of insulin therapy and the cost of complications treatment (hypoglycemia). During the budget impact analysis, the source of data on the target population was the registry of patients with diabetes mellitus of the Russian Federation. Probabilistic sensitivity analysis was performed to assess the impact of changes in the input parameters of the models. Results. Insulin aspart+nicotinamide has a clinical advantage in the effective- ness of HbA1c reduction in type 1 diabetes population. In patients with type 2 diabetes, the effectiveness of insulin aspart+nicotinamide and insulin aspart is comparable by a similar criterion. Direct medical costs of insulin aspart+nicotinamide are 10.64% lower in comparison with insulin aspart use in type 1 and type 2 diabetes patients’ population. The CER value in type 1 diabetes patient population for insulin aspart is 70% higher compared to insulin aspart+nicotinamide (7,410,353.83 and 4,348,513.94 RUR respectively). Budget impact analysis results are the following: that complete replacement of insulin aspart with insulin aspart+nicotinamide over 3 years is accompanied by a 5.3% reduction of regional drug benefit budget costs. Conclusion. The clinical and economic analysis confirms the economic feasibility of insulin aspart + nicotinamide use

Insulin aspart

10.30809/phe.4.2021.1

Cite

Citations (0)

PCN260 REVIEW OF BREAST CANCER MATHEMATIC AND EPIDEMIOLOGY MODELS

Value in Health (2019)

Y. Yurkova А. А. Курылев А. С. Колбин

10.1016/j.jval.2019.09.455

Cite

Citations (0)

HEALTH-ECONOMIC ANALYSIS OF IDEGASP CO-FORMULATION (RYZODEG®) COMPARING WITH OTHER INSULIN TREATMENT REGIMENS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

Pharmacoeconomics theory and practice (2020)

А. С. Колбин А. А. Курылев Yu. Е. Balykina М. А. Проскурин M.V. Globin

10.30809/phe.4.2020.3

Cite

Citations (1)

Pharmacogenetics of schizophrenia in real clinical practice: a clinical case

Neurology neuropsychiatry Psychosomatics (2018)

Р. Ф. Насырова N. A. Schnaider К. О. Миронов German A. Shipulin О. П. Дрибноходова

Schizophrenia is a socially significant mental disorder characterized by early onset and high time and financial expenditure on treatment. The basic drugs in these patients are antipsychotics that are highly effective against the positive and negative symptoms of schizophrenia, but at the same time have a wide range of adverse reactions (ARs). The clinical effect and tolerability of antipsychotics are variable and depend on the characteristics of genetically determined mechanisms (transportation, biotransformation, and elimination). The paper describes a clinical case of a female patient with schizophrenia who has been noted to be unresponsive to antipsychotic therapy for some years after the onset of the disease. After pharmacogenetic testing, she was found to be homozygous for the nonfunctional allelic variant CYP2D6*4 (1934 G>A, rs3892097), which was the reason for the complete shutdown of isoenzyme 2D6 activity and the development of ARs in the use of initial doses of antipsychotic drugs, as well as for an increase in the severity of ARs with aggravation of psycho-producing symptoms with an even slow titration of the daily dose.

Tolerability

10.14412/2074-2711-2018-4-88-93

Cite

Citations (12)

Parametric and Non-Parametric Approaches for Predicting Bacterial Resistance

Value in Health (2016)

M Arepieva А. С. Колбин А. А. Курылев Yu. Е. Balykina Anna Spiridonova

Consumption

Parametric model

10.1016/j.jval.2016.09.552

Cite

Citations (0)

Health-economic analysis of tocilizumab in patients with rheumatoid arthritis and systemic juvenile arthritis

Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice (2020)

А. С. Колбин А. А. Курылев S. А. Mishinova Yu. Е. Balykina М. А. Проскурин

Rationale . Rheumatoid arthritis (RA) and systemic juvenile arthritis (sJA) are the most frequent rheumatic diseases in adults and adolescents, consequently. Biologics disease modifying antirheumatic drugs (bDMARDs) are eff ective in treatment of RA and s JA. Aim . To perform health-economic analysis of tocilizumab for subcutaneous and intravenous injections in patients with RA and sJA comparing to TNF-α inhibitors. Materials and methods . Cost-minimizing analysis was used from the perspective of healthcare system (accounting for direct medical costs) with the modelling horizon — 1 year. We included into the model cost of RA and sJA bDMARDs, cost of adverse events correction and costs of laboratory and instrumental diagnostic. Results . Cost minimizing ratio of tocilizumab (subcutaneous form) in RA patients comparing to adalimumab (Humira), сertolizumab pegol, golimumab were 111 536; 129 094; 85 244 RUR, consequently favour to tocilizumab. Tocilizumab was less costly comparing to adalimumab (Humira), certolizumab pegol, golimumab by 12.8, 14.5, 10,0 %, consequently. Cost minimizing ratio of tocilizumab in RA patients comparing to adalimumab (Dalibra), etanercept, infl iximab (Remicade) were 40 497; 54 355; 28 419 RUR in favour to comparators. Tocilizumab was more costly comparing to adalimumab (Dalibra) etanercept, infl iximab (Remicade) by 5.6; 7.7; 3.9 %, consequently. Cost minimizing ratio of tocilizumab in sJA patients comparing to kanakinumab, adalimumab (Humira) and adalimumab (Dalibra) were 6 535 234; 478 297 and 323 263 RUR. Tocilizumab was less costly comparing to kanakinumab, adalimumab (Humira) and adalimumab (Dalibra) by 93.3; 50.6 and 41.1 %, consequently. Conclusions . Tocilizumab is economically reasonable comparing to others TNF-α inhibitors in patients with RA and sJA.

Tocilizumab

Golimumab

Certolizumab pegol

Abatacept

10.37489/2588-0519-2020-1-23-33

Cite

Citations (1)

Budget Impact Analysis of the Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors – Nilotinib in the First and Second Lines of Therapy

Value in Health (2015)

А. С. Колбин M. Yu. Frolov А. А. Курылев I. A. Vilum Yu. Е. Balykina

The goal of the study was to evaluate clinical and economic feasibility of nilotinib in comparison with the imatinib usage as the first-line therapy for chronic myeloid leukaemia (CML), and implementation of nilotinib compared with imatinib in high doses in the second-line treatment. Health-economic analysis and budget impact analysis of the use of tyrosine kinase inhibitors (TKI) for CML treatment were performed in Russian economic conditions. Economic models for the first and the second lines of CML treatment were built separately. Analysis showed that use of nilotinib for patients with newly diagnosed CML as the first-line treatment and for patients with imatinib resistance or intolerability as the second-line treatment is accompanied by 36% increase of consolidated budget expenditures in 2015 compared to 2014 in theoretical consumption calculations. In terms of real consumption, use of nilotinib leads to 16% increase in consolidated budget expenditures in 2015, in comparison with 2014. Expected budget expenditure in 2015, taking into account actual consumption, is 5.8 billion RUB. The growth of state expenditure for CML treatment might be due to increase in the number of patients and the use of the second-generation TKI. In case of nilotinib use, with consideration of remission that allows therapy cancellation, the average cost of one CML patient treatment based on all lines of therapy in the registry per year will be decreased by 6% in 2018 compared to 2015, despite an increase in the number of patients in the registry. Nilotinib is characterized by greater efficiency in the both lines of therapy. Using of the second-generation TKI, including nilotinib, can lead to stable remission with possible therapy cancellation after two or three years from the moment of deep molecular response. It may lead to the stabilization of cost per patient in the registry by 2018.

Chronic myeloid leukaemia

10.1016/j.jval.2015.09.1095

Cite

Citations (0)

Систематический обзор математических моделей, применяемых для прогнозирования развития резистентности бактерий к антибиотикам

Клиническая микробиология и антимикробная химиотерапия (2014)

М А Арепьева А. С. Колбин А. А. Курылев Ю Е Балыкина С В Сидоренко

Source

Cite

Citations (0)

Review of methods for assessing the cost-effectiveness of medical interventions

Real-World Data & Evidence (2025)

T. I. Busheva А. А. Курылев

Assessment of the effectiveness of a drug is a complex process. Currently, the standard method for assessing the effectiveness of a medical intervention is the quality-adjusted life years (QALY). In the summer of 2024, a description of a new method for assessing the effectiveness of medical interventions — Standard of Living Valuation (SoLV) was published. The proposed method is more difficult than QALY, but its capabilities are broader. However, this method is also not optimal. The problem of creating an optimal method for assessing the cost-effectiveness of health technologies remains open.

10.37489/2782-3784-myrwd-057

Cite

Citations (0)

Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation

DOAJ (DOAJ: Directory of Open Access Journals) (2018)

А. С. Колбин А. А. Курылев Yu. Е. Balykina М. А. Проскурин

Dabrafenib

Mutation Testing

Source

Cite

Citations (0)